KRYSTAL‑7 Ⅱ期研究：一线阿达格拉西布联合帕博利珠单抗治疗晚期/转移性KRAS G12C突变非小细胞肺癌（NSCLC）患者

First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

报告人： Pasi A. Jänne, PhD | Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

摘要编号：8500

TROPION‑Lung02：Dato‑DXd联合帕博利珠单抗±铂类化疗用于晚期NSCLC一线治疗

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).

报告人：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine

摘要编号：8501

CAMPASS：贝莫苏拜单抗联合安洛替尼 vs. 帕博利珠单抗用于晚期NSCLC一线治疗的随机、单盲、多中心 Ⅲ期研究

CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.

报告人：韩宝惠  | 上海市胸科医院

摘要编号：LBA8502

Zipalertinib在接受过含铂化疗±无埃万妥单抗治疗的 EGFR 外显子20插入突变NSCLC患者中的疗效评估

Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

报告人：Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center

摘要编号：8503

SOHO‑01：BAY 2927088 在既往接受治疗但未接受过 HER2 靶向治疗或对晚期疾病尚未进行任何治疗的 HER2 突变NSCLC患者中的安全性与疗效研究

SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.

报告人：Herbert H. Loong, MBBS, FRCP, FASCO | 香港中文大学

摘要编号：8504

SACHI Ⅲ期研究：赛沃替尼联合奥希替尼对比化疗用于 EGFR 突变且 MET 扩增的晚期NSCLC患者（在 EGFR TKI治疗失败后）的随机对照结果

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

报告人：陆舜 | 上海市胸科医院

摘要编号：LBA8505

HERTHENA‑Lung02 Ⅲ期研究：Patritumab deruxtecan（HER3‑DXd）用于对三代 EGFR TKI 耐药的 EGFR 突变晚期NSCLC患者

Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

报告人：莫树锦 | 香港中文大学 

摘要编号：8506

OptiTROP‑Lung03：芦康沙妥珠单抗在既往治疗过的 EGFR 突变晚期NSCLC患者中的应用——随机对照研究结果

Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.

报告人：张力 | 中山大学肿瘤防治中心

摘要编号：8507

CheckMate 816：可切除NSCLC患者术前 纳武利尤单抗+ 化疗对总体生存的影响

Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816

报告人：Patrick M. Forde, MD, PhD | Trinity St. James’s Cancer Institute, Trinity College Dublin

摘要编号：LBA8000

NeoADAURA：可切除EGFRm NSCLC术前新辅助奥希替尼± 化疗vs 单纯化疗的对比研究

Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA

报告人：Jamie E. Chaft, MD, FASCO | Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College

摘要编号：8001

密西西比三角洲地区肺癌筛查与偶然发现肺结节队列中的肺癌诊断率研究 

Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta

报告人：Raymond U. Osarogiagbon, MBBS, FACP, FASCO | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program

摘要编号：8002

高危早期NSCLC诱导/巩固期阿替利珠单抗  + SBRT 对比单纯 SBRT 的随机 Ⅲ期试验

Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC (SWOG/NRG S1914)

报告人：Megan Eileen Daly, MD | Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center

摘要编号：8003

R‑ALPS：TQB2450 单药或联合安罗替尼维持治疗局部晚期不可手术（Ⅲ期）NSCLC 患者（同期或序贯化放疗后无进展）的随机、双盲、安慰剂对照多中心 Ⅲ期临床试验

A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy

报告人：陈明 | 中山大学肿瘤防治中心

摘要编号：LBA8004

局限期小细胞肺癌（SCLC）化放疗后使用阿替利珠单抗是否延长生存的随机 Ⅱ期试验

Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)

报告人：Bjorn Henning Gronberg, MD, PhD | Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology and Department of Oncology, St. Olavs Hospital

摘要编号：LBA8005

IMforte Ⅲ期研究：芦比替定+ 阿替利珠单抗作为广泛期小细胞肺癌（ES‑SCLC）患者一线维持治疗的主要结果

 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial

报告人：Luis G. Paz-Ares, MD, PhD | Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc

摘要编号：8006

ZG006 Ⅱ期扩展剂量研究：针对 CD3/DLL3 的三特异性 T 细胞接合器 ZG006 单药治疗晚期SCLC患者的研究

A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer

报告人：艾星浩 | 上海市胸科医院

摘要编号：8007

DeLLphi‑304 Ⅲ期主要分析：塔拉妥单抗 vs 化疗作为SCLC二线治疗

Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

报告人：Charles M. Rudin, MD, PhD | Fiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center

摘要编号：LBA8008